Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab. - Shimizu T; Kawashiri SY; Koga T; Kiya R; Morita M; Kuroda S; Tashiro S; Morimoto S; Yano H; Ueki Y; Dobashi H; Nozaki Y; et al. (Global health & medicine, 2025)